Cargando…
Comment on “immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab”
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438887/ https://www.ncbi.nlm.nih.gov/pubmed/36053341 http://dx.doi.org/10.1007/s10238-022-00883-4 |
| _version_ | 1784781926987464704 |
|---|---|
| author | Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj |
| author_facet | Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj |
| author_sort | Mungmunpuntipantip, Rujittika |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9438887 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94388872022-09-06 Comment on “immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab” Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj Clin Exp Med Letter to the Editor Springer International Publishing 2022-09-02 /pmc/articles/PMC9438887/ /pubmed/36053341 http://dx.doi.org/10.1007/s10238-022-00883-4 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj Comment on “immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab” |
| title | Comment on “immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab” |
| title_full | Comment on “immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab” |
| title_fullStr | Comment on “immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab” |
| title_full_unstemmed | Comment on “immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab” |
| title_short | Comment on “immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab” |
| title_sort | comment on “immune response to sars-cov-2 mrna vaccines in patients treated with either ibrutinib or rituximab” |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438887/ https://www.ncbi.nlm.nih.gov/pubmed/36053341 http://dx.doi.org/10.1007/s10238-022-00883-4 |
| work_keys_str_mv | AT mungmunpuntipantiprujittika commentonimmuneresponsetosarscov2mrnavaccinesinpatientstreatedwitheitheribrutiniborrituximab AT wiwanitkitviroj commentonimmuneresponsetosarscov2mrnavaccinesinpatientstreatedwitheitheribrutiniborrituximab |